Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previously healthy~* Age ≤12 months at the time of randomization~* Weight ≤10 kg at the time of randomization~* Gestational age ≥36 weeks~* RSV illness (must have coryza) documented by a positive RSV test at the time of evaluation~* Documented stable clinical condition that does not require hospitalization (oxygen saturation ≥ 95%; respiratory rate \< 60 breaths/minute in children \< 2 months and \< 50 breaths/minute in children 2-12 months)~* Respiratory Distress Assessment Instrument (RDAI) score of ≤ 6 (there can be no more than 1 point assigned for each of the 6 assessment categories) at baseline evaluation~* Randomization within 4 hours of being evaluated with a positive Binax® RSV test~* Written informed consent obtained from the participant's parent(s) or legal guardian~Exclusion Criteria:~* Prior receipt of or receiving treatment with steroids (except topical steroids) prior to randomization~* Prior medically diagnosed RSV infection~* Prior receipt of or receiving anti-viral treatment for the current episode of RSV infection prior to randomization~* Any medically significant underlying ongoing chronic illness or organ system dysfunction or other known acute illness, other than the acute RSV infection~* Known renal impairment, hepatic dysfunction, hematologic abnormalities, seizure or other neurologic disorder or immunodeficiency~* Requirement for supplemental oxygen (brief use of oxygen in the immediate postnatal period to treat a transient condition is allowed)~* Mechanical ventilation at any time prior to the onset of the current RSV infection~* Congenital heart disease \[children with medically or surgically closed patent ductus arteriosus (PDA), small atrial septal defect (ASD) or small ventricular septal defect (VSD) will be allowed\]~* Previous reaction to intravenous immunoglobulin (IVIG), blood products, or other foreign proteins~* Prior use of IVIG, RSV-IGIV (RespiGam®), motavizumab or other immunoglobulin products within the past 2 months~* Prior use of palivizumab (Synagis®) within the past 2 months~* Currently receiving other investigational agents or have received any other investigational agents within the last 3 months~* Prior or current participation in any investigational study with a therapeutic agent or vaccine for RSV

- Gender: ALL
- Minimum Age: 0 Months
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- Motavizumab (Type: EXPERIMENTAL): Participants will receive a single IM dose of 30 mg/kg of motavizumab on Day 0 of the study.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive a single IM dose of placebo matched to motavizumab on Day 0 of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).